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Abstract
Introduction: Weight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons
with HIV (PWH) to cardio-metabolic disease. We assessed relationships between ART drug class and weight change among
treatment-na€ıve PWH initiating ART in the North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD).
Methods: Adult, treatment-na€ıve PWH in NA-ACCORD initiating integrase strand transfer inhibitor (INSTI), protease inhibitor
(PI) or non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based ART on/after 1 January 2007 were followed through 31
December 2016. Multivariate linear mixed effects models estimated weight up to five years after ART initiation, adjusting for
age, sex, race, cohort site, HIV acquisition mode, treatment year, and baseline weight, plasma HIV-1 RNA level and CD4+ cell
count. Due to shorter follow-up for PWH receiving newer INSTI drugs, weights for specific INSTIs were estimated at two
years. Secondary analyses using logistic regression and all covariates from primary analyses assessed factors associated with
>10% weight gain at two and five years.
Results: Among 22,972 participants, 87% were male, and 41% were white. 49% started NNRTI-, 31% started PI- and 20%
started INSTI-based regimens (1624 raltegravir (RAL), 2085 elvitegravir (EVG) and 929 dolutegravir (DTG)). PWH starting
INSTI-based regimens had mean estimated five-year weight change of +5.9kg, compared to +3.7kg for NNRTI and +5.5kg for
PI. Among PWH starting INSTI drugs, mean estimated two-year weight change was +7.2kg for DTG, +5.8kg for RAL and
+4.1kg for EVG. Women, persons with lower baseline CD4+ cell counts, and those initiating INSTI-based regimens had higher
odds of >10% body weight increase at two years (adjusted odds ratio = 1.37, 95% confidence interval: 1.20 to 1.56 vs.
NNRTI).
Conclusions: PWH initiating INSTI-based regimens gained, on average, more weight compared to NNRTI-based regimens. This
phenomenon may reflect heterogeneous effects of ART agents on body weight regulation that require further exploration.
Keywords: integrase inhibitors; weight gain; obesity; metabolic; HIV; North America
Additional information may be found under the Supporting Information tab for this article.
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1 | INTRODUCTION
Weight gain following antiretroviral therapy (ART) initiation is
common among persons with HIV (PWH), particularly those
with more pronounced CD4+ cell count (CD4) depletion or
lower pre-ART body mass index (BMI) [1-3]. In the early ART
era, weight gain on treatment was often seen as evidence of
nutritional rehabilitation and was associated with improved
survival and immunologic recovery [3-5]. However, over the
past two decades the BMI of PWH on ART has steadily
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increased. In one multisite United States (US) study, over half
of those remaining on treatment at three years were over-
weight or obese [1]. Among PWH, a high BMI is associated
with an increased risk of developing diabetes, neurocognitive
impairment, and other comorbid conditions [6-9], and the
avoidance of weight gain may reduce these risks.
Integrase strand transfer inhibitors (INSTI; e.g. raltegravir
(RAL), elvitegravir (EVG), dolutegravir (DTG) and bictegravir
(BIC)) are a more recently available class of antiretroviral
medications with a good tolerability profile and, for DTG and
BIC, a substantial genetic barrier to the emergence of HIV
drug resistance [10,11]. INSTI-based ART regimens are now
the recommended first-line treatment for most PWH [12], but
several recent studies, primarily from single sites or cohorts,
report greater weight gain among persons receiving INSTI-
based ART regimens for initial therapy as compared to pro-
tease inhibitor (PI) and non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimens. In a cohort from Brazil,
PWH receiving RAL-based regimens were sevenfold more
likely to become obese (BMI ≥ 30kg/m2) compared to those
receiving NNRTI- or PI-based regimens [13]. In other observa-
tional studies, INSTI-based regimens generally, and particularly
DTG-based ART regimens [14-17], were also associated with
greater weight gain. In the prospective AIDS Clinical Trial
Group (ACTG) study A5257, the use of RAL with tenofovir
disoproxil fumarate and emtricitabine (TDF/FTC) as an initial
ART regimen was associated with greater increases in waist
circumference and increased odds of a >10% weight gain at
96 weeks, compared to ART regimens including ritonavir-
boosted darunavir or ritonavir-boosted atazanavir, each com-
bined with TDF/FTC [18,19].
ART-associated weight gain among PWH may contribute to
an increased risk of cardiometabolic disease, but the magni-
tude of weight gain associated with use of different initial
ART regimens has varied in recent studies [14,20]. Given the
clinical implications of higher body weight on long-term health
and the broad adoption of INSTI-based ART regimens as rec-
ommended first-line therapy, further data are needed describ-
ing weight trajectories among large numbers of PWH starting
different ART regimens and who are diverse in terms of sex,
race/ethnicity and age. Herein, we use the North American
AIDS Cohort Collaboration on Research and Design (NA-
ACCORD), which pools longitudinal data from multiple regions
of the United States and Canada, to conduct a rigorous analy-
sis of weight changes over time and investigate risk factors
for weight gain among over 20,000 treatment-naive PWH
who initiated ART.
2 | METHODS
NA-ACCORD, one of the regional cohorts supported by the
International epidemiologic Databases to Evaluate AIDS
(IeDEA) consortium sponsored by the National Institutes of
Health, is a multi-site collaboration involving 26 cohort studies
representing over 200 clinical and research facilities in the
United States and Canada [21]. PWH are eligible to be
enrolled in the NA-ACCORD from contributing cohorts if they
have ≥2 clinical visits within 12 months. NA-ACCORD collects
individual-level standardized data on demographic and clinical
characteristics, ART use, laboratory measurements, medical
diagnoses and vital status. These data are pooled, harmonized
and undergo quality control procedures for accuracy and com-
pleteness at the central Data Management Core (University
of Washington, Seattle, WA, USA), followed by additional qual-
ity control procedures and assembly into analytic-ready sum-
mary files at the Epidemiology/Biostatistics Core (Johns
Hopkins University, Baltimore, MD, USA). Submission of data
to NA-ACCORD requires institutional review board (IRB)
approval at each participating site, and as data are de-identi-
fied (except for dates) a waiver of consent is obtained. The
review and approval to conduct this specific NA-ACCORD
analysis was provided by the Vanderbilt University IRB.
For this analysis, we utilized NA-ACCORD data on ART-
naive adults who initiated a first regimen that contained an
NNRTI, PI or INSTI in combination with dual nucleoside/nu-
cleotide reverse transcriptase inhibitors (NRTIs) between 1
January 2007 and 31 December 2016, and had available
baseline weight and height information. The date of ART initia-
tion was considered the first occurrence of sustained ART use
for more than 45 days. Participants were classified as ART-
naive if there was no recorded ART exposure of more than
45 days prior to the start of a combination NNRTI-, PI- or
INSTI-based regimen (this included review of all available
records prior to 2007) and the viral load at treatment initia-
tion was detectable (≥400 copies/mL). Women who had previ-
ously received ART in the antenatal period were considered
“na€ıve” only if their prior ART exposure was for <45 days.
The primary aim of this analysis was to assess the relation-
ship between ART class and weight over time among treat-
ment-na€ıve participants. Analyses were conducted separately
among: (1) the full group of participants who met inclusion cri-
teria, where initial ART was categorized by class as NNRTI-,
PI- or INSTI-based; (2) the sub-group of participants who initi-
ated an INSTI-based regimen, categorized as RAL, DTG or
EVG; and (3) the sub-group of participants who initiated
either an NNRTI- or PI-based regimen, or RAL, DTG or EVG.
For each analysis, NA-ACCORD sites with fewer than 50
PWH who initiated each ART class/INSTI drug were excluded
from the analysis. Additionally, participants on regimens con-
taining more than one major ART class (e.g. NNRTI and INSTI)
were also excluded from the analysis.
Demographic and clinical characteristics were summarized
across the ART/drug categorization using median (interquar-
tile range) or percent with frequency, as appropriate. Kruskal-
Wallis tests assessed the associations of continuous variables
with the ART class/drug; Pearson’s chi-squared tests assessed
association between categorical variables and ART class/drug.
We modelled weight changes over time using multivariate
linear mixed effects models treating each participant as a ran-
dom effect. Participants were censored at the time of a switch
to a new ART class (i.e. not including NRTI switches or within-
class switches) or at the first instance of virologic failure. Viro-
logic failure was defined as a plasma HIV-1 RNA >1000
copies/mL, or at the first of two consecutive detectable HIV-1
RNA measurements ≥400 copies/mL after previously being
virologically suppressed [12]. Models adjusted for ART class/
drug (not including NRTI backbone), years since ART initiation,
sex assigned at birth, self-reported race, HIV risk factor, age,
baseline weight, baseline CD4 (square-root transformed),
baseline HIV-1 RNA (log10-transformed), cohort site and year
of ART initiation. Interactions between ART class/drug and
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years since ART initiation, sex, race and HIV risk factor were
assessed. To relax linearity assumptions, years since ART initi-
ation, age, and baseline weight, CD4 and HIV-1 RNA were
modelled using restricted cubic splines with five knots. Base-
line weight and CD4 were the values closest to ART initiation
within a window of 180 to +30 days. Baseline HIV-1 RNA
was the value closest to ART initiation within a window of
180 to +7 days. Self-reported race was dichotomized as
white versus non-white. HIV risk factor was classified as men
who have sex with men (MSM), persons who inject drugs
(PWID, including MSM/PWID), heterosexual and other/un-
known. Missing baseline data were multiply imputed using 10
imputation replications. Marginal predicted weights over time
along with 95% bootstrapped confidence intervals (CIs) were
calculated by ART class/drug and the predicted weights at
two and five years after ART initiation were reported.
In secondary analyses, to further explore the relationship
between weight over time and ART use, we assessed weight
gain in excess of 10% at two and five years post-ART initiation
by regimen class, and at two years by individual INSTI medica-
tions. Weight at two and five years was defined as the weight
closest to those time points and within a window of
6 months. Persons with missing baseline and follow-up
weight were excluded from these secondary analyses. Using
>10% weight gain as an outcome, we used multivariate logistic
regression adjusting for the same covariates used in the pri-
mary analysis. As in the primary analysis, continuous variables
were fit with restricted cubic splines using five knots; how-
ever, in this analysis no interaction terms were included. Miss-
ing data were multiply imputed with 10 imputation
replications.
Lastly, we evaluated the proportion of participants who
transitioned between the standard BMI categories of normal
(18.5 to 24.9kg/m2), overweight (25.0 to 29.9kg/m2) and
obese (≥30kg/m2) after three years of ART. Analyses were
performed using R (version 3.4.4; www.r-project.org).
3 | RESULTS
A total of 22,972 ART-naive PWH who started treatment
between 2007 and 2016 and met inclusion criteria were avail-
able from 13 cohorts in NA-ACCORD. The study population
was 87% male and 41% white. Median age at ART initiation
was 42 years, BMI 25kg/m2, CD4 count 308 cells/mm3 and
log10 HIV-1 RNA 4.6 copies/mL. Table 1A shows baseline
characteristics of participants by ART class (NNRTI, PI and
INSTI) at treatment initiation. Of the 22,972 PWH, 11,296
(49%) starting NNRTI-based regimens, 7038 (31%) PI-based
regimens and 4638 (20%) INSTI-based regimens. PWH initiat-
ing INSTI-based regimens were younger, more likely to report
MSM as their probable HIV risk factor, had higher CD4, and
initiated ART later (2014) than those initiating NNRTI- and
PI-based regimens (2010). The majority of persons across all
three groups had tenofovir-based NRTI backbones, which was
predominantly TDF with only 130 participants (0.7%) receiv-
ing tenofovir alafenamide fumarate (TAF). The low use of TAF
is likely a reflection of the cohort close date of 31 December
2016.
Among PWH who initiated an INSTI-based regimen, 28%
received RAL, 22% received DTG and 50% received
EVG (Table 1B). Persons initiating RAL were older and had
lower baseline CD4 compared to those starting EVG or DTG.
Additionally, median year of ART initiation was earlier for RAL
(2011) compared to DTG (2015) and EVG (2014). The major-
ity of regimens containing RAL and EVG were co-formulated
with TDF, while most DTG-based regimens were co-formu-
lated with abacavir.
Individuals receiving PI- and INSTI-based regimens gained
more weight on average than those starting NNRTI-based regi-
mens (Figure 1); while there was clear separation in the CIs
for NNRTIs versus INSTIs and PIs, there was considerable
overlap in 95% CIs for the estimated weights of the latter two
drug classes. At two and five years, persons on INSTI-based
regimens gained an estimated mean of 4.9 and 5.9kg respec-
tively compared to 4.9 and 5.5kg among persons who received
PI-based regimens, and 3.1 and 3.7kg among NNRTI-based
regimen recipients (Table S1). Within the INSTI class, RAL- and
DTG-based regimens were associated with higher estimated
mean weight gain than EVG-based regimens (Figure 2), though
intervals for the estimated mean weights on RAL and DTG lar-
gely overlapped. At two years, persons starting RAL-based reg-
imens gained an average of 5.8kg compared to 7.2kg among
persons who received DTG-based regimens, and 4.1kg among
EVG-based regimen recipients. Changes in weight over two
years among PWH starting individual INSTI drugs compared to
those starting PI- or NNRTI-based regimens is shown in Fig-
ure S1. While the estimated mean weight gain for of each of
the INSTI drugs was greater than NNRTI-based regimens at
two years, the 95% CIs for weight gain on the individual INSTI
drugs largely overlapped with the PI-based regimens.
Among male participants weight gain was greater among
INSTI-based ART compared to PI-based ART, albeit with over-
lapping 95% CIs, whereas for female participants weight gain
was similar for recipients of INSTI- and PI-based regimens
(Figure 3a). When the interaction of race and ART regimen
type was assessed, INSTI-associated weight gain was greater
than PI-associated weight gain only for non-whites whereas
INSTI-associated change was slightly lower than PI-associated
change for whites, though both differences were well within
the overlapping Cls (Figure 3b).
Figure 4 reports the adjusted odds of a >10% weight gain,
compared to baseline, at two and five years among all persons
starting ART (Figure 4a), and at two years for those initiating
specific INSTI drug-based regimens (Figure 4b). Among all
ART initiators, the odds of a >10% weight gain were substan-
tially higher for PWH starting PI- and INSTI-based regimens
compared to NNRTI-based regimens at both years 2 and 5.
Women and younger persons had higher odds for a >10%
weight gain at two years, while at five years the odds contin-
ued to be higher for these groups though the associations
were attenuated. However, the probability of a >10% weight
gain at two years was non-linear and highest for those with
an age of approximately 33 years, which then declined before
plateauing between ages 45 and 50 years (Figure S2). Nota-
bly, the odds of a >10% weight gain were similar between
white and non-white persons, but a lower baseline weight and
CD4 were independent predictors of this degree of weight
gain at two and five years. When restricting the analysis to
participants starting INSTI-based regimens, the odds of a
>10% weight gain at year 2 were significantly lower for par-
ticipants receiving EVG compared to RAL.
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A substantial proportion of participants transitioned
between BMI categories after ART initiation. After three years
of ART, 32% of normal-BMI PWH who initiated an INSTI-
based regimen had become overweight, compared to 29% of
those on a PI-based regimen and 25% on a NNRTI-based regi-
men (Figure S3). Rates of transition from overweight to obese
after three years of ART use were 28%, 26% and 22% for
recipients of INSTI, PI and NNRTI-based ART respectively.
Transitioning to a lower BMI category was observed with all
ART regimens, though at a much lower frequency than transi-
tioning to higher BMI categories.
4 | DISCUSSION
This is the largest observational study to date evaluating asso-
ciations between initial ART regimens and subsequent weight
gain among ART-na€ıve PWH. Our findings highlight greater
weight gain at two and five years among persons who
received INSTI-based regimens compared to NNRTI-based
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Figure 1. Weight over the first five-years of ART by regimen class.
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regimens. Moreover our findings indicate differential risk for
weight gain associated with use of specific INSTI drugs, which
was higher among DTG and RAL recipients compared to per-
sons receiving EVG.
Weight gain after ART initiation was often favourably
regarded as a “return to health” phenomenon earlier in the
HIV epidemic. More recently, with longer survival having
become routine among ART-treated PWH, an increasing pro-
portion of individuals ultimately become overweight or obese
after ART initiation. [1,6,9,22,23]. Among ART-na€ıve persons,
weight gain after ART initiation tends to be greater among
those with lower baseline BMI, higher HIV-1 viral load and
lower CD4 [1]. The origin of this weight gain is multifactorial
and may result from a reduction in inflammation-related cata-
bolism, lower basal energy expenditure, changes in dietary
habits or other behaviours (e.g. access to smoking cessation
treatment) among other factors [24,25]. Nevertheless, findings
from our study and from similar smaller studies indicate that
initial ART agents exert independent effects on weight gain
over time as well.
Several demographic characteristics have been associated
with increased risk of weight gain among PWH receiving INSTI-
based initial ART regimens. In the prospective ACTG study
A5257, the use of RAL with TDF/FTC as an initial regimen was
associated with a greater increase in waist circumference at
96 weeks, compared to ritonavir-boosted darunavir and riton-
avir-boosted atazanavir, each combined with TDF/FTC [18].
Women and persons of black race who received RAL-based ART
experienced greater increases in waist circumference compared
to the PI-based ART recipients. In another study evaluating
weight gain following switch to INSTI-based regimens among
virally suppressed ACTG participants in protocols A5001 and
A5322, female sex, black race and older age were all associated
with greater annualized weight gain after switch to INSTI [26].
Similarly, in the current study we found that female sex, lower
baseline weight and lower baseline CD4 were factors associated
with significantly higher odds of a >10% weight gain at two and
five years after ART initiation.
Among patients receiving INSTI-based regimens, these find-
ings corroborate our prior report from a smaller Southeastern
US cohort in which we described greater weight gain associ-
ated with DTG-based ART regimen use [14], as well as reports
from other observational cohorts [15-17]. Moreover similar
disparities in weight gain by initial ART regimen type were
noted in a recent 48-week, open-label, randomized trial con-
ducted in South Africa comparing EFV/TDF/FTC versus DTG
with TDF/FTC or with TAF/FTC, which reported greater
increases over 48 weeks in weight and truncal fat among
DTG compared to EFV recipients, particularly among persons
also receiving TAF. Notably, women were distinctly more
prone to truncal fat increases and obesity over 48 weeks
compared to men [20]. Lastly, a recent randomized, double-
blind, multi-centre trial comparing BIC- versus DTG-based
ART reported comparable weight gain between the two
groups at 96 weeks, but no participants received non-INSTI-
based ART regimens to serve as comparators [27].
In this study, the overwhelming majority of participants
received ART regimens containing TDF or abacavir, and prior
studies have not observed substantially different weight changes
with use of these two NRTIs [28,29]. Notably, <1% of
(a)
(b)
Figure 4. Adjusted odds of a >10% weight increase at two and five years among all participants starting ART (a). Adjusted odds of a >10% weight
increase at two years among participants starting INSTI-based regimens (b). (1) Logistic regression model included in addition to the variables listed:
baseline HIV-1 RNA, cohort site, HIV risk acquisition group and year of ART initiation. (2) Results in (a) are from logistic regression model including all
patients with available weight data at year 2 (N = 15,467) and year 5 (N = 6578). (3) Results in (b) are from logistic regression model including only
patients on INSTI with available weight data at year 2 (N = 2314). ART, antiretroviral therapy; DTG, dolutegravir; EVG, elvitegravir; INSTI, integrase
strand transfer inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; RAL, raltegravir.
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participants received an ART regimen containing TAF. The use of
TAF, approved in the US in November 2015, is rapidly increasing
given the lower incidence of adverse bone and renal effects com-
pared to TDF. Recent data from pooled clinical trials and other
studies indicate that TAF use predisposes to weight gain inde-
pendent of concomitant INSTI use [20,30,31]. The very low num-
ber of participants receiving TAF is both a strength and a
limitation of our study. By essentially excluding TAF recipients
our analysis was able to identify more fully the effects of INSTI
drug use on weight change after ART initiation, though additional
analyses will be needed in the future to assess the potential con-
tribution of TAF to ART-associated weight gain.
Some caution is warranted in interpreting the findings from
this study, as our observational cohort was drawn from multi-
ple sites in North America and results may not be generaliz-
able to all PWH, particularly in non-US/Canadian settings.
Additionally, based on the Food and Drug Administration
approval date for DTG, we limited the analysis of variation in
weight gain by individual INSTI drugs to two years, and our
analysis period preceded the introduction of BIC. Moreover
our analysis did not adjust for exposure to non-HIV medica-
tions associated with weight gain (e.g. hormonal and psy-
chotropic drugs) nor did we adjust for pregnancy, as these
data were not routinely collected in the cohort. Furthermore,
only 13% of participants were females; therefore, we might
be misrepresenting the population-level impact of weight gain
in the target population of HIV positive individuals initiating
ART in the United States and Canada during this period –
especially as several studies have shown ART-associated
weight gain to be a greater problem among females [20,30].
Finally, we did not assess clinical outcomes, such as metabolic
or cardiovascular disease incidence or progression, and future
studies will be needed to determine the impact of the
observed weight changes on the health of PWH. Further stud-
ies are also needed to evaluate the mechanism of weight gain
among patients starting INSTI-based regimens. With the cur-
rent available evidence, it remains unclear whether the weight
gain is secondary to off-target effects of these drugs and a
toxicity, or whether it’s due to the higher effectiveness, safety
and tolerability of these medications.
5 | CONCLUSION
In this multisite cohort of over 20,000 diverse treatment-
na€ıve PWH across North America who initiated ART, we
found that the use of INSTI-based ART regimens was associ-
ated with higher weight gain up to five years after treatment
initiation compared to NNRTI-based regimens, primarily dri-
ven by the use of DTG- and RAL-containing regimens. Addi-
tionally, INSTI-based ART was associated with comparable
weight gain to PI-based regimens. ART-treated PWH have a
high prevalence of obesity and are already at greater risk for
metabolic and cardiovascular comorbidities; closely monitoring
changes in weight after the initiation of INSTI-class drugs may
identify patients who could benefit from weight loss interven-
tions and closer scrutiny of associated cardio-metabolic risks.
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Figure S1. Changes in weight within the first two-years of
ART initiation among PWH starting different INSTI- drugs
compared to those starting PI- or NNRTI-based regimens.
Figure S2. Predicted probability of >10% weight gain after
two years of ART by age and regimen class.
Figure S3. Transition between the BMI categories of under-
weight (<18.5kg/m2), normal BMI (18.5 to 24.9kg/m2), over-
weight (25.0 to 29.9kg/m2) and obese (≥30kg/m2) over three
years of ART by regimen class.
Table S1. Predicted weight (95% confidence interval) and pre-
dicted change in weight compared to baseline for persons
with HIV starting different ART regimens.
Bourgi K et al. Journal of the International AIDS Society 2020, 23:e25484
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25484/full | https://doi.org/10.1002/jia2.25484
8
